Horus Pharma Becomes Additional Commercialization Partner for Formycon’s Eylea® Biosimilar FYB203 in Selected European Countries under the Brand Name Baiama®
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
